Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsBOM:533573 +0.31%75 Days Payable is 143.19 as of Mar. 2026, which is 9% above its 10-year median of 130.87. GuruFocus rates BOM:533573 with a GF Score™ of 75/100 and a GF Value™ of ₹1,054.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 925 Drug Manufacturers companies, Alembic Pharmaceuticals ranks better than 77.51% on this metric.
The historical rank and industry rank for Alembic Pharmaceuticals's Days Payable or its related term are showing as below:
BOM:533573'
s Days Payable Range Over the Past 10 Years
Min: 0.25 Med: 130.87 Max: 176.41
Current: 159.55
During the past 13 years, Alembic Pharmaceuticals's highest Days Payable was 176.41. The lowest was 0.25. And the median was 130.87.
BOM:533573's Days Payable is ranked better than 77.51% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:533573: 159.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alembic Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (BOM:533573) has a Days Payable of 143.19 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alembic Pharmaceuticals and its competitors. This is near median its historical median of 130.87. Over the past decade, Alembic Pharmaceuticals' Days Payable has ranged from 0.25 to 176.41. According to the industry distribution chart, Alembic Pharmaceuticals ranks #208 out of 925 companies in the Drug Manufacturers industry, placing it in the top 22.5%.
Is Alembic Pharmaceuticals' Days Payable too high?
Alembic Pharmaceuticals' current Days Payable of 143.19 is near median its 10-year median of 130.87. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 176.41. The Drug Manufacturers industry median Days Payable is 90.38. Alembic Pharmaceuticals' value of 143.19 is 58.4% above this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #208 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alembic Pharmaceuticals has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #208 out of 925 companies for Days Payable. This places Alembic Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Alembic Pharmaceuticals' value of 143.19 is 58.4% above this benchmark. Historically, Alembic Pharmaceuticals' own Days Payable has ranged from 0.25 to 176.41 over the past decade. While the company's 10-year median is 130.87 vs. the industry median of 90.38, Alembic Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current Days Payable of 143.19 is 58.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current Days Payable is 143.19, which is near median its own 10-year median of 130.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,054.49, compared to a current price of ₹796.50 — trading 24.5% below its estimated fair value. The current Days Payable is 143.19, which is near median its 10-year median of 130.87 and 58.4% above the Drug Manufacturers industry median of 90.38. Alembic Pharmaceuticals' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current Days Payable is 143.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹796.50 is trading 24.5% below its estimated GF Value™ of ₹1,054.49.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:533573:
Days Payable: 143.19 (near median its 10-year median of 130.87)
GF Value™: ₹1,054.49 vs. price of ₹796.50 (24.5% below fair value)
Industry Position: 58.4% above the Drug Manufacturers median (#208 of 925)
No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
75GF Score
Get the complete analysis for BOM:533573
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533573 has been successfully added to your 
